全球肽和抗凝药物市场 – 行业趋势和 2029 年预测

市场分析和规模                              

冠心病和心肌梗塞（MI）被视为全球主要的公共卫生问题。在美国，患有冠心病的患者数量明显增加。根据美国心脏协会（AHA）的数据，2018 年美国大约每七人中就有一人死亡。根据调查，患有心脏感染的成年人占近 790 万（3%）。因此，肽和抗凝药物市场的需求急剧增加。

Data Bridge Market Research 分析称，2021 年肽和抗凝药物市场价值为 15.3 亿美元，预计到 2029 年将达到 24.5 亿美元，在 2022 年至 2029 年的预测期内复合年增长率为 6.10%。除了市场价值、增长率、细分市场、地理覆盖范围、市场参与者和市场情景等市场洞察外，Data Bridge Market Research 团队策划的市场报告还包括深入的专家分析、患者流行病学、管道分析、定价分析和监管框架。

报告范围和市场细分

Market Definition

Blood thinners are anticoagulants, which are chemical agents that inhibit blood coagulation and blood clotting time. Anticoagulants are a pharmacological class of drugs used to treat thrombotic diseases. Oral anticoagulants come in pill, tablet, and injectable dose forms. Herapins, low molecular weight heparins (LMWHs), warfarin, direct thrombin inhibitors and factor Xa inhibitors are the most common anticoagulants (DTIs). Heparin is an injectable anticoagulant commonly used in hospitals to prevent blood clotting. Subcutaneous injections of LMWHs are given twice a day to treat DVT. Peptides, also known as amide bonds, are long-chain amino acids bound together by peptide bonds. Peptides are a special class of medicinal substances that are molecularly made up of tiny molecules and proteins. The therapeutic characteristics of peptides are deployed to treat a variety of disorders.

Peptide and Anticoagulant Drugs Market Dynamics

Drivers

• Increasing cases of coronavirus infection globally

The rising coronavirus infection cases globally are anticipated to drive the peptide and anticoagulant drugs market's growth. According to new research, hypercoagulability in those infected by the coronavirus disease (COVID-19) pandemic could be one of the major causes of death globally. As a result, the rising number of instances is driving up demand for anticoagulant medications to treat thrombosis in critically unwell or hospitalized patients.

• Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of peptide and anticoagulant drugs market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.

• Increasing prevalence of cardiovascular diseases

The increased prevalence of cardiovascular diseases will fuel industry growth. The rise in cardiovascular disorders is propelling the industry forward. Cardiovascular diseases are a major driver of market expansion. Cardiovascular disorders are the main cause of death worldwide, accounting for about 18.6 million deaths in 2019, as per the Heart Disease and Stroke Statistics Update Fact Sheet published in 2021. Each year, cardiovascular disorders cause more deaths than cancer and chronic lower respiratory disease (CLRD) combined. Additionally, increasing prevalence of chronic diseases in both the elderly and middle-aged populations is estimated to propel the market's growth rate.

Furthermore, surging geriatric population and rise in the number of infected patients globally will result in the expansion of peptide and anticoagulant drugs market. Along with this, the sedentary lifestyle of people such as rising addiction of smoking and extended sitting and favourable reimbursement policies will enhance the growth rate of the market.

Opportunities

• Technological advancement

The industry is projected to benefit from technological advancements in the development of anticoagulant products. Advanced technologies such as microfluidics, fluorescent microscopy, electrochemical sensing, photoacoustic detection, and micro/nano electromechanical systems (MEMS/NEMS) have been used to develop highly accurate, robust, and cost-effective anticoagulant products, according to a study published in the Frontier in Biotehnology and Bioengineering in December 2019.

Moreover, the market's growth is fueled by an increase in the number of research and development activities and emerging new markets. These factors will provide beneficial opportunities for the peptide and anticoagulant drugs market growth.

Restraints/Challenges

• Side effects linked with anticoagulants

Anticoagulant side effects may stymie market growth over the projection period. Heparin-induced thrombocytopenia causes the immune system to produce antibodies against the body's own platelets, which increases the risk of bleeding. For illustration, the FDA gets roughly 450,000 adverse medication events per year, with 3.8 percent of those involving heparin, reducing market income. Warfarin can also cause chrondrodysplasia punctata, asplenia, and foetal malformations, among other things. The industry's value will be harmed by such side consequences. Despite the fact that important market leaders are attempting to develop novel products, side effects may reduce their acceptance rate.

On the other hand, the high cost associated with drug development and distribution will obstruct the market's growth rate. The lack of healthcare infrastructure in developing economies and the dearth of skilled professionals will challenge the market of peptide and anticoagulant drugs. Additionally, lack of awareness among people and strict government regulations will restrain and further impede the growth rate of the market during the forecast period of 2022-2029.

This peptide and anticoagulant drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the peptide and anticoagulant drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Peptide and anticoagulant drugs market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Peptide and Anticoagulant Drugs Market

由于研究速度快，预计 COVID-19 感染将显著影响肽和抗凝药物市场。根据 2020 年发表在《美国心血管药物杂志》上的一项研究，正在进行十多项临床试验，以评估抗凝剂在 COVID-19 患者中的潜力，并且正在研究将这些药物用于重症 COVID-19 患者的肠外给药策略。此外，根据 2021 年 1 月发布的世界卫生组织更新，确诊和疑似 COVID-19 患者应能够接受低剂量抗凝剂的后续护理。因此，COVID-19 期间抗凝剂需求激增。

近期发展

• 2020 年 12 月，Natco Pharma 宣布推出一款名为利伐沙班 (RPIGAT) 的抗凝药物。利伐沙班是一种治疗和预防血栓的抗凝药物。在印度，拜耳将该药物作为 Xarelto 销售。

全球肽类及抗凝药物市场范围

肽类和抗凝药物市场根据类型、适应症、低分子量肝素类型、给药途径、最终用户和分销渠道进行细分。这些细分市场之间的增长情况将帮助您分析行业中增长缓慢的细分市场，并为用户提供有价值的市场概览和市场洞察，帮助他们做出战略决策，确定核心市场应用。

低分子肝素类

• 肝素钠
• 依诺肝素钠
• 达肝素钠
• 磺达肝癸钠

类型

• 荷尔蒙
• 抗生素
• 血管紧张素转换酶 (ACE) 抑制剂
• 抗真菌
• 其他的

指征

• 糖尿病
• 传染病
• 癌症
• 骨质疏松症
• 心脏病学
• 妇科
• 其他的

给药途径

• 口服
• 注射剂
• 其他的

最终用户

• 医院
• 专科诊所
• 家庭护理
• 其他的

分销渠道

• 医院药房
• 零售药店
• 网上药店
• 其他的

肽和抗凝药物市场区域分析/见解

对肽和抗凝药物市场进行了分析，并按国家、类型、适应症、低分子量肝素类型、给药途径、最终用户和分销渠道提供了市场规模见解和趋势。

肽和抗凝药物市场报告涵盖的国家包括北美的美国、加拿大和墨西哥、欧洲的德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区 (APAC) 的其他地区、沙特阿拉伯、阿联酋、南非、埃及、以色列、中东和非洲 (MEA) 的其他地区、南美洲的巴西、阿根廷和南美洲的其他地区

北美在市场份额和市场收入方面占据肽和抗凝药物市场的主导地位，并将在预测期内继续保持主导地位。这是因为对疾病特定治疗的需求不断增长，医疗支出不断增加，这将进一步推动该地区市场的增长率。此外，主要关键参与者的不断增加以及新技术的采用率的提高将进一步推动该地区市场的增长率。

由于亚太地区老年人口数量激增，预计该地区将成为 2022-2029 年预测期内增长最快的地区。此外，医疗保健基础设施的发展和政府举措的不断增加将进一步推动该地区市场的增长率。

报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。   

竞争格局和肽类及抗凝药物市场份额分析

肽和抗凝血药物市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对肽和抗凝血药物市场的关注有关。

肽和抗凝药物市场的一些主要参与者包括：

• F. Hoffmann-La Roche Ltd.（瑞士）
• Mylan NV（美国）
• Teva Pharmaceutical Industries Ltd.（爱尔兰）
• 赛诺菲（法国）
• 辉瑞公司（美国）
• 葛兰素史克公司 (英国)
• 诺华公司（瑞士）
• 默克公司（美国）
• 艾尔建（爱尔兰）
• 阿斯利康（英国）
• 强生私人有限公司（美国）
• Hikma Pharmaceuticals PLC（英国）
• 费森尤斯卡比公司（德国）
• 卫材株式会社（日本）
• 百时美施贵宝公司 (美国)
• 拜耳公司（德国）
• 第一三共株式会社（日本）
• 勃林格殷格翰国际有限公司（德国）
• Dr. Reddy's Laboratories Ltd.（印度）
• 阿斯彭控股 (南非)

SKU-53318